Exhibits
S-1
from S-1
284 pages
S-1
01/17/25
EX-3.1
from S-1
27 pages
Amended and Restated Certificate of Incorporation of Sionna Therapeutics, Inc
01/17/25
EX-3.3
from S-1
15 pages
By-Laws of Sling Therapeutics, Inc
01/17/25
EX-4.1
from S-1
2 pages
Indenture or similar
01/17/25
EX-4.2
from S-1
32 pages
Amended and Restated Investors’ Rights Agreement
01/17/25
EX-10.1
from S-1
54 pages
Sionna Therapeutics, Inc. 2020 Stock Option and Grant Plan
01/17/25
EX-10.5
from S-1
3 pages
Sionna Therapeutics, Inc. Senior Executive Cash Incentive Bonus Plan
01/17/25
EX-10.6
from S-1
15 pages
Sionna Therapeutics, Inc. Severance and Change in Control Plan Effective Date: [Month] [Date], 2024
01/17/25
EX-10.8
from S-1
7 pages
Sionna Therapeutics, Inc. Compensation Recovery Policy Adopted as of [ ], 2024, Subject to Effectiveness of the Company’s Registration Statement on Form S-1 for Its Initial Public Offering
01/17/25
EX-10.9
from S-1
61 pages
Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed. License Agreement Between Sanofi and Sling Therapeutics, Inc. Dated as of December 20, 2019
01/17/25
EX-10.10
from S-1
71 pages
Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed. License Agreement Between Abbvie Global Enterprises Ltd. and Sionna Therapeutics, Inc. Effective July 11, 2024 Confidential
01/17/25
EX-10.11
from S-1
34 pages
Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed. Payment Agreement Between Cystic Fibrosis Foundation and Sling Therapeutics, Inc. Dated as of December 20, 2019
01/17/25
EX-10.12
from S-1
5 pages
March 8, 2021 Michael J. Cloonan [Omitted] Re: Employment Offer Dear Michael: On Behalf of Sling Therapeutics, Inc., a Delaware Corporation (The “Company”), I Am Pleased to Offer You the Position of the Company’s President and Chief Executive Officer and (“CEO”). if Accepted, This Letter Agreement Sets Forth the Terms and Conditions of Your Employment (The “Agreement”)
01/17/25
EX-10.13
from S-1
7 pages
May 7, 2021 Charlotte M. McKee, M.D. [Omitted] Re: Employment Offer Dear Charlotte
01/17/25
EX-10.14
from S-1
5 pages
August 20, 2021 Elena Ridloff [Omitted] Re: Employment Offer Dear Elena: On Behalf of Sling Therapeutics, Inc., a Delaware Corporation (The “Company”), I Am Pleased to Offer You the Position of the Company’s Chief Financial Officer and (“CFO”). if Accepted, This Letter Agreement Sets Forth the Terms and Conditions of Your Employment (The “Agreement”)
01/17/25
EX-10.15
from S-1
86 pages
Genesis 21 Hickory Lease Bp3-Bos6 21 Hickory LLC, a Delaware Limited Liability Company, as Landlord, and Sionna Therapeutics, Inc., a Delaware Corporation, as Tenant Summary of Basic Lease Information
01/17/25
EX-21.1
from S-1
1 page
Subsidiaries of the registrant
01/17/25
EX-23.1
from S-1
1 page
Consent of expert or counsel
01/17/25
EX-FILING FEES
from S-1
~1
page
01/17/25
Graphics & Data Files
GRAPHIC
from S-1
g882384g00a01.jpg
01/17/25
GRAPHIC
from S-1
g882384g00t61.jpg
01/17/25
GRAPHIC
from S-1
g882384g01g01.jpg
01/17/25
GRAPHIC
from S-1
g882384g01g72.jpg
01/17/25
GRAPHIC
from S-1
g882384g01g73.jpg
01/17/25
GRAPHIC
from S-1
g882384g01g74.jpg
01/17/25
GRAPHIC
from S-1
g882384g01g95.jpg
01/17/25
GRAPHIC
from S-1
g882384g01n48.jpg
01/17/25
GRAPHIC
from S-1
g882384g01t01.jpg
01/17/25
GRAPHIC
from S-1
g882384g02a02.jpg
01/17/25
GRAPHIC
from S-1
g882384g02g02.jpg
01/17/25
GRAPHIC
from S-1
g882384g02n46.jpg
01/17/25
GRAPHIC
from S-1
g882384g03t00.jpg
01/17/25
GRAPHIC
from S-1
g882384g04a65.jpg
01/17/25
GRAPHIC
from S-1
g882384g05s34.jpg
01/17/25
GRAPHIC
from S-1
g882384g06f39.jpg
01/17/25
GRAPHIC
from S-1
g882384g07t61.jpg
01/17/25
GRAPHIC
from S-1
g882384g08l68.jpg
01/17/25
GRAPHIC
from S-1
g882384g08m08.jpg
01/17/25
GRAPHIC
from S-1
g882384g09g09.jpg
01/17/25
GRAPHIC
from S-1
g882384g11m11.jpg
01/17/25
GRAPHIC
from S-1
g882384g12s01.jpg
01/17/25
GRAPHIC
from S-1
g882384g12s02.jpg
01/17/25
GRAPHIC
from S-1
g882384g20m08.jpg
01/17/25
GRAPHIC
from S-1
g882384g21m12.jpg
01/17/25
GRAPHIC
from S-1
g882384g21m21.jpg
01/17/25
GRAPHIC
from S-1
g882384g22m12.jpg
01/17/25
GRAPHIC
from S-1
g882384g22p22.jpg
01/17/25
GRAPHIC
from S-1
g882384g24p45.jpg
01/17/25
GRAPHIC
from S-1
g882384g36f36.jpg
01/17/25
GRAPHIC
from S-1
g882384g40w31.jpg
01/17/25
GRAPHIC
from S-1
g882384g47t79.jpg
01/17/25
GRAPHIC
from S-1
g882384g51w71.jpg
01/17/25
GRAPHIC
from S-1
g882384g63e34.jpg
01/17/25
GRAPHIC
from S-1
g882384g64n17.jpg
01/17/25
GRAPHIC
from S-1
g882384g79q02.jpg
01/17/25
GRAPHIC
from S-1
g882384g88x73.jpg
01/17/25
GRAPHIC
from S-1
g882384g88y21.jpg
01/17/25
GRAPHIC
from S-1
g882384g91a54.jpg
01/17/25
